Part A - Single Ascending Dose (SAD) in Healthy Human Volunteers

Preclinical

Part A - Single Ascending Dose (SAD) in Healthy Human Volunteers is one of 2 therapeutic programs targeting Axial Spondyloarthritis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Axial SpondyloarthritisRecruiting

Axial SpondyloarthritisPreclinical

Recruiting

Competition

Competitive Landscape

4 competitors in Axial Spondyloarthritis

#DrugCompanyPhaseTrials

Cimzia

UCB

Approved

1 2

Part A - Single Ascending Dose (SAD) in Healthy Human Volunteers

GGrey Wolf Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Axial Spondyloarthritis

NCT07047703

Clinical

Trials by Indication[1]

Axial Spondyloarthritis1 trial

A Multi-part, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD0715 in Healthy Human Volunteers and Participants With Axial Spondyloarthritis

Recruiting·GGrey Wolf Therapeutics·Preclinical·NCT07047703·141 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Part A - Single Ascending Dose (SAD) in Healthy Human Volunteers. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Part A - Single Ascending Dose (SAD) in Healthy Human Volunteers. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Grey Wolf Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: GGrey Wolf Therapeutics

Part A - Single Ascending Dose (SAD) in Healthy Human Volunteers

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Axial Spondyloarthritis1 trial

References

Drug Info

Quick Facts

Related News